Clinical Trials Browser

Terminated × Adenocarcinoma × Everolimus × Clear all

NCT01784861 2021-07-08

VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Everolimus for Treating Patients With Pancreatic Neuroendocrine Tumors

Phase 1/2 Terminated

23 enrolled 17 charts

Gastrointestinal

Adenocarcinoma, Pancreatic Neoplasms